1544 related articles for article (PubMed ID: 31301321)
1. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
2. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
3. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
4. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
[TBL] [Abstract][Full Text] [Related]
5. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
6. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
[TBL] [Abstract][Full Text] [Related]
7. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
[TBL] [Abstract][Full Text] [Related]
8. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
9. The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and β-cell Function.
Semnani-Azad Z; Connelly PW; Johnston LW; Retnakaran R; Harris SB; Zinman B; Hanley AJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):e285-94. PubMed ID: 31677389
[TBL] [Abstract][Full Text] [Related]
10. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
11. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
[TBL] [Abstract][Full Text] [Related]
12. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects.
Zanni MV; Burdo TH; Makimura H; Williams KC; Grinspoon SK
Clin Endocrinol (Oxf); 2012 Sep; 77(3):385-90. PubMed ID: 22098563
[TBL] [Abstract][Full Text] [Related]
13. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults.
Wei Y; Liu J; Wang G; Wang Y
Biol Sex Differ; 2023 Oct; 14(1):69. PubMed ID: 37814297
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD163: a biomarker linking macrophages and insulin resistance.
Parkner T; Sørensen LP; Nielsen AR; Fischer CP; Bibby BM; Nielsen S; Pedersen BK; Møller HJ
Diabetologia; 2012 Jun; 55(6):1856-62. PubMed ID: 22450890
[TBL] [Abstract][Full Text] [Related]
16. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P.
Caviglia GP; Rosso C; Armandi A; Gaggini M; Carli F; Abate ML; Olivero A; Ribaldone DG; Saracco GM; Gastaldelli A; Bugianesi E
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266488
[No Abstract] [Full Text] [Related]
17. Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice.
Dong B; Zhou Y; Wang W; Scott J; Kim K; Sun Z; Guo Q; Lu Y; Gonzales NM; Wu H; Hartig SM; York RB; Yang F; Moore DD
Hepatology; 2020 May; 71(5):1559-1574. PubMed ID: 31506976
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163 is associated with CD163 mRNA expression in adipose tissue and with insulin sensitivity in steady-state condition but not in response to calorie restriction.
Kračmerová J; Rossmeislová L; Kováčová Z; Klimčáková E; Polák J; Tencerová M; Mališová L; Štich V; Langin D; Šiklová M
J Clin Endocrinol Metab; 2014 Mar; 99(3):E528-35. PubMed ID: 24423341
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
Ortiz-Lopez C; Lomonaco R; Orsak B; Finch J; Chang Z; Kochunov VG; Hardies J; Cusi K
Diabetes Care; 2012 Apr; 35(4):873-8. PubMed ID: 22374640
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli A
Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
